SMA Alfamino Hypoallergenic Infant Formula

Product Information

Cekola P, et al.Clinical use and safety of an amino acid-based infant formula in areal worldsetting. Abstract presented at NASPGHAN. Chicago, IL, USA, October 2019. If you are concerned that your child may have CMPA, speak with your child’s doctor to discuss symptoms and possible diagnosis. In case of a severe allergic reaction, seek medical assistance without delay. Once diagnosed, CMPA can be effectively managed in consultation with a healthcare professional. The key is to seek support from a healthcare professional as early as possible in the journey to ensure an early and correct diagnosis. Nowak-Wegrzyn A, et al. ConfirmedHypoallergenicityof a Novel Whey-Based ExtensivelyHydrolyzedInfant Formula Containing Two Human Milk Oligosaccharides. Nutrients 2019;11(7):E1447. ALFAMINO® is an infant formula product for special dietary use and must be used under medical supervision. It is not suitable for general use.

In Australia and New Zealand more than 2% (1 in 50) of infants are allergic to cow's milk*. Most children outgrow cow's milk allergy by the age of three to five years. Although nearly half of the children affected by CMPA grow out of it by 1 year, and two-thirds at 2, we understand that in the initial stages it can be a very challenging time as a parent. Host A and Halken S. Cow's milk allergy: where have we come from and where are we going? Endocr Metab Immune Disord Drug Targets 2014;14(1):2-8.Luyt D, et al. BSACI guideline for the diagnosis and management of cow’s milk allergy. Clin Exp Allergy 2014;44(5):642-672.

SMA® Alfamino® is a hypoallergenic amino acid based powdered formula with added medium chain triglycerides. An infant food for special medical purposes, intended for the dietary management of severe/complex symptoms of cows’ milk protein allergy (CMPA) and/or multiple food protein. Complete nutritional support from birth or supplementary feeding from 6 months and up to 3 years of age. What is Cows’ Milk Protein Allergy (CMPA)? Koletzko S, et al. Diagnostic Approach and Management of Cow’s-Milk Protein Allergy in Infants and Children: ESPGHAN GI Committee Practical Guidelines. J Pediatr Gastroenterol Nutr 2012;55(2):221-229. Vandenplas Y, et al. Safety and adequacy of an optimized formula for pediatric patients with cow’s milk-sensitive enteropathy. Minerva Pediatr. 2010;62(4)339–45.Vandenplas Y, et al. Safety and adequacy of a semi-elemental formula for children with gastro-intestinal disease. Amino Acids. 2010;38(3):909–14. Niggemann, B., et al. Safety and efficacy of a new extensively hydrolysed formula for infants with cow’s milk protein allergy. Pediatr Allergy Immunol, 2008. 19(4): p. 348-54.

Azad MB et al. Human Milk Oligosaccharide Concentrations Are Associated with Multiple Fixed and Modifiable Maternal Characteristics, Environmental Factors, and Feeding Practices J Nutr 2018;148(11):1733-1742. West CE, et al. The gut microbiota and its role in the development of allergic disease: a wider perspective Clin Exp Allergy 2015;45(1):43–53. IgE mediated –rapid onset allergic reactions and can occur within 15 minutes after consuming cows’ milk or dairy products.Bode L. Human milk oligosaccharides: Every baby needs a sugar mama. Glycobiology 2012;22(9):1147-1162.